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j ourna l homepage: www.eb iomed ic ine.comEditorialNeglected Tropical Diseases: Research Bites BackProgress toward the treatment of three major parasitic diseases
(sleeping sickness, Chagas disease, and leishmaniasis) was recently
demonstrated in an article published online last month in the journal
Nature (August 8, 2016). Collectively, these three diseases affect 20mil-
lion people per year, resulting in 50 thousand deaths. Researchers were
able to identify and optimize a small molecule that selectively inhibited
the parasite proteasomes, and yet did not inhibit human proteasomes.
This gives some hope that with further development, the drug may ef-
fectively treat those infected with these parasites without having toxic
effects on the patients. These three diseases are known to be caused
by genetically similar kinetoplastid parasites, and are part of a larger
group of what are referred to as neglected tropical diseases (NTDs). Re-
searchers discovered this promising new compound by screening a li-
brary of 3 million small molecules, and found that mice given the
optimized drug were able to effectively clear the parasites in preclinical
infectionmodels. Althoughwe are still a longway from seeing this drug
applied in the clinic, the idea that a single drug could have such broad-
spectrum activity against three highly prevalent NTDs is encouraging–
particularly since the available treatments for these diseases are not
well tolerated and/or easily administered.
NTDs are a diverse group of more than a dozen diseases that collec-
tively affect more than a billion people–mostly the poor–primarily in
developing countries with limited resources. Other NTDs include (but
are not limited to) schistosomiasis, lymphatic ﬁlariasis (elephantiasis),
onchocerciasis (river blindness), trachoma, dengue and rabies, as well
as helminth-related diseases such as roundworm, whipworm, and
hookworm. In 2012, the World Health Organization issued a strategic
road map for elimination and/or effective control for many of these
NTDs by 2020. This goal has been backed with resources and ﬁnancial
support in collective efforts from major pharmaceutical companies,
non-proﬁt agencies such as the Gates Foundation, PATH, and the
Drugs for Neglected Diseases Initiative, as well as several academic
and governmental agencies. This massive, collaborative effort is of the
scale and breadth needed to tackle such as huge undertaking, and the
goal is not insurmountable. Treatments for several NTDs are in fact al-
ready available, yet will need proper infrastructure for distribution as
well as accurate testing and epidemiological analyses for effective im-
plementation and monitoring. Vector and non-human host identiﬁca-
tion and control, clean water access, and other hygiene and sanitation
methodsmust also be implemented effectively to reach this goal. In ad-
dition to thesewell-deﬁned strategic goals, the complex goals of identi-
fying new treatments and vaccines are likely to require amore in-depth
investment of time and resources.
As alluded to above, one reason targeted proteasome inhibition is so
exciting as a treatment approach is that the available treatments forhttp://dx.doi.org/10.1016/j.ebiom.2016.09.009
2352-3964/© 2016 Published by Elsevier B.V. This is an open access article under the CC BY-NCthese threeNTDs are not ideal. Currentmedicines for late-stage sleeping
sickness can be toxic and difﬁcult to administer. Although a combina-
tion treatment of nifurtimox and eﬂornithine has reduced the complex-
ity of eﬂornithine intravenous regiments, it is effective against only one
of two forms of African trypanosomiasis, and the only effective treat-
ment for the rhodesiense form is quite toxic, and in fact sometimes dead-
ly. Chagas disease can be treated by both benznidazole and nifurtimox,
but patients must be treated early to be effective. Treatment is also
counter-indicated in pregnant women and patients with psychiatric
disorders or by patients with kidney or liver failure. Treatment for
visceral leishmaniasis also has potentially serious side effects, and can
be costly. So although drugs are available, there is much room for
improvement.
Other NTDs have relatively safe and cost-effective treatments avail-
able, such as praziquantel for the treatment of schistosomiasis, and iver-
mectin (and now possibly doxycycline) for river blindness. The strategy
for controlling this category of NTDs has typically been mass, repeated
chemotherapy for high-risk populations. The key challenges here are
identifying all those at risk and getting them treatment, as well as con-
trolling the vectors (such as snails and black ﬂies) that carry the
infectious pathogens. And even though treatment is available for river
blindness, there is still a need for new drugs, as co-infection with eye
worm can cause adverse reactions to ivermectin. Also, the effectiveness
of doxycycline-related inhibition of the adult parasitic worm in
preventing blindness needs further study.
Vaccine development for NTDs is another area of great need and op-
portunity, as even those NTDs with safe and effective drugs will likely
need additional preventive measures to fully bolster effective disease
control and elimination. Although vaccines are currently under devel-
opment for several NTDs (such as helminth infections, dengue virus,
and kinetoplastid-related diseases), ﬁnancial support and investment
have not nearly approached the scale needed to fully develop, test,
and implement vaccines for most NTDs.
We commend the efforts many have made thus far in the battle
against this group of diseases that affect the world's neediest. In this
issue, we present a paper from Lukehart and colleagues that examines
whether ﬂies may play a role as a vector in the transmission of yaws
and other treponemal NTDs. At EBioMedicine, we aim to contribute the
goal of eliminating and controlling NTDs by promoting and publishing
studies aimed at optimizing NTD therapies and at identifying new treat-
ments, and by working toward improved measures of monitoring and
control of these diseases, their hosts, and their vectors of transmission.
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